Five Prime names ex-Genentech I-O specialist research SVP

Bryan Irving replaces Luis Borges as SVP of research. (Courtesy of Five Prime)

Five Prime Therapeutics has appointed Bryan Irving, Ph.D., as its SVP of research. Irving made his name in the industry in a decadelong stint at Genentech, during which he performed research that gave rise to anti-PD-L1 antibody Tecentriq.

South San Francisco, CA-based Five Prime landed Irving after persuading him to swap a VP position at neighboring CytomX Therapeutics for a chance to lead its research effort. Irving spent 4 years in roles of increasing responsibility at CytomX. But unless that work results in a major product, he will remain best known for his research at a company whose buildings are all around those of his current and former employer: Genentech.

Irving swapped an academic career in which he helped develop CAR technology for a role at Genentech in 2001, initially to study lupus and Type 1 diabetes. After 4 years, Irving pivoted to research tumor-specific T cells, leading him to file a patent on the use of anti-PD-L1 antibodies to enhance the function of T cells.  

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

That work ultimately led to Tecentriq, the late-to-the-party anti-PD-L1 drug Genentech and parent company Roche see as the cornerstone of their immuno-oncology plans.

Management at Five Prime is now looking to Irving to unearth similar successes from its research platform. 

“Five Prime has built an unparalleled proprietary library of more than 5,700 human extracellular proteins containing the majority of medically relevant protein drug targets. I look forward to applying my experience in immuno-oncology to this platform in an effort to identify new targets, which could translate into multiple therapeutic proteins,” Irving said in a statement.

Irving replaces Luis Borges, Ph.D. Borges joined Five Prime as senior director in 2014 after 12 years at Amgen, after which a series of promotions led him to take the SVP of research post 11 months ago. Five Prime listed Borges as holding the SVP post as recently as August 12. But his name has now vanished from the management roster and is absent from the release unveiling the appointment of Irving. 

Suggested Articles

By employing heart rate signals, physical activity and sleep quality, common Fitbit trackers may be able to predict the spread of the flu.

Nanox has raised $26 million to help fuel the development and commercialization of its Star Trek-inspired digital X-ray bed.

Oncology is clearly a major medical and societal issue, but one that sees too much focus from biopharmas at the expense of other killers.